MARKET INSIGHTS

Global (R)-4-Methyl-1-phenylethylamine (CAS 4187-38-6) market size was valued at USD 28.4 million in 2025. The market is forecasted to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(R)-4-Methyl-1-phenylethylamine (CAS 4187-38-6) is a chiral amine belonging to the phenylethylamine family, characterized by a single stereocenter that confers distinct optical activity. This enantiomerically pure building block is widely employed as a chiral resolving agent and as an intermediate in asymmetric synthesis, particularly in the production of pharmaceuticals, agrochemicals, and fine chemicals. Its structural properties make it especially valuable in the development of optically active drug substances where stereochemical precision is critical.

The market is witnessing steady growth driven by the expanding demand for enantiopure compounds in pharmaceutical manufacturing and the broader adoption of asymmetric synthesis methodologies across the specialty chemicals sector. The increasing emphasis on chiral purity in regulatory frameworks governing active pharmaceutical ingredients continues to reinforce demand for high‑quality chiral amines such as this compound. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Alfa Aesar, among other fine chemical manufacturers maintaining robust portfolios of chiral building blocks.

(R)-4-Methyl-1-phenylethylamine (CAS 4187-38-6) Market – View in Detailed Research Report

Top 10 Companies

1. Finetech Industry Limited

Headquarters: Shanghai, China
Key Offering: High‑purity (R)-4-Methyl-1‑phenylethylamine for pharmaceutical intermediates

Finetech Industry Limited has established a reputation for large‑scale production of enantiopure amines. Its state‑of‑the‑art chiral resolution facilities deliver consistent yields above 95%, meeting the stringent impurity limits required for API development. The company’s focus on process efficiency translates into competitive pricing for both technical and pharmaceutical‑grade material.

Sustainability & Growth Initiatives:

• Investments in continuous‑flow hydrogenation to reduce solvent use and energy consumption.
• Partnerships with contract research organizations to co‑develop novel chiral catalysts.
• Implementation of ISO 9001 and ISO 14001 certifications to reinforce quality and environmental stewardship.

2. Enamine LLC

Headquarters: Kropyvnytskyi, Ukraine
Key Offering: GMP‑grade chiral building blocks for drug discovery

Enamine’s portfolio includes a range of chiral amines tailored for medicinal chemistry. The firm leverages asymmetric organocatalysis to produce enantiomerically pure intermediates with high enantiomeric excess, supporting late‑stage diversification in lead optimization.

Sustainability & Growth Initiatives:

• Adoption of bio‑based solvents in resolution processes.
• Collaborations with academic institutions to explore novel biocatalytic routes.
• Continuous improvement of waste‑management protocols to achieve zero‑hazard waste.

3. Hairui Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Custom synthesis of chiral amines for fine‑chemical applications

Hairui Chemical provides tailored synthesis services, enabling clients to access bespoke chiral intermediates at scale. The company’s modular synthesis platform supports rapid turnaround for emerging therapeutic candidates.

Sustainability & Growth Initiatives:

• Deployment of renewable energy sources across production sites.
• Implementation of advanced process monitoring to reduce raw‑material waste.
• Strategic alliances with regional pharmaceutical hubs to streamline supply chains.

4. Biosynth AG

Headquarters: Basel, Switzerland
Key Offering: High‑purity chiral amines for API synthesis

Biosynth AG delivers premium‑grade chiral amines that meet the most demanding regulatory specifications. The firm’s focus on green chemistry aligns with European environmental directives, enhancing its appeal to EU‑based pharma manufacturers.

Sustainability & Growth Initiatives:

• Investment in asymmetric hydrogenation with 100% renewable electricity.
• Development of recyclable catalyst systems to lower operational costs.
• Participation in EU Horizon 2025 projects for sustainable chemical production.

5. Matrix Scientific

Headquarters: Boston, USA
Key Offering: Custom chiral amine synthesis for research and development

Matrix Scientific specializes in small‑batch, high‑purity chiral intermediates, catering to academic and industrial research laboratories. The company’s flexible manufacturing model supports rapid prototyping for early‑stage drug discovery.

Sustainability & Growth Initiatives:

• Implementation of green chemistry principles in all synthesis routes.
• Collaboration with biotechnology firms to develop enzyme‑based chiral resolutions.
• Adoption of digital twin technology to optimize process efficiency.

6. Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Scalable production of pharmaceutical‑grade (R)-4‑Methyl‑1‑phenylethylamine

Shanghai Trustin Chemical has built a robust production line capable of meeting high‑volume demand while maintaining strict purity controls. The firm’s integration of real‑time analytics ensures consistent batch quality across all grades.

Sustainability & Growth Initiatives:

• Use of compressed‑air‑driven reactors to reduce carbon footprint.
• Development of closed‑loop solvent recovery systems.
• Engagement with local universities to train the next generation of chiral chemists.

7. Apollo Scientific Ltd.

Headquarters: London, United Kingdom
Key Offering: GMP‑grade chiral amines for drug development

Apollo Scientific’s portfolio focuses on high‑purity intermediates that support the synthesis of complex APIs. The company’s rigorous quality management framework ensures compliance with both UK and EU regulatory standards.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient distillation units.
• Partnerships with environmental NGOs to monitor lifecycle emissions.
• Investment in carbon‑offset projects to achieve net‑zero emissions.

8. J&H Chemical

Headquarters: Guangzhou, China
Key Offering: Custom chiral amine synthesis for agrochemical applications

J&H Chemical provides high‑purity chiral intermediates tailored for agrochemical synthesis, supporting the development of next‑generation pesticides with reduced environmental impact.

Sustainability & Growth Initiatives:

• Adoption of biocatalytic resolution processes to lower hazardous waste.
• Collaboration with agritech firms to develop eco‑friendly crop protection agents.
• Implementation of water‑recycling systems in manufacturing units.

9. TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: Technical‑grade chiral amines for specialty chemical research

TCI Chemicals offers a broad range of technical‑grade chiral amines used in research laboratories and pilot‑scale production. The firm’s focus on process optimization delivers cost‑effective solutions for early‑stage development.

Sustainability & Growth Initiatives:

• Implementation of green chemistry metrics across all facilities.
• Partnerships with Japanese universities to advance asymmetric catalysis.
• Use of renewable energy sources for all production sites.

10. Alfa Aesar

Headquarters: Houston, USA
Key Offering: Research‑grade chiral amines for academic and industrial use

Alfa Aesar supplies a wide array of chiral amines for research and development, supporting both academic laboratories and industrial R&D efforts. The company’s emphasis on product consistency makes it a trusted supplier in the scientific community.

Sustainability & Growth Initiatives:

• Reduction of solvent usage through advanced purification techniques.
• Investment in high‑efficiency chromatography systems.
• Participation in global sustainability initiatives to lower overall carbon footprint.

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307603/methylphenylethylamine-market

Get Full Report Here: https://www.24chemicalresearch.com/reports/307603/methylphenylethylamine-market

Market Outlook 2026‑2034

The forecast period is marked by a steady expansion of demand for enantiopure intermediates, driven by the launch of new CNS and oncology therapeutics that require precise stereochemical control. Supply chains are increasingly resilient, with multi‑sourcing strategies mitigating raw‑material volatility. Regulatory momentum continues to favor single‑enantiomer drugs, reinforcing the premium placed on high‑purity chiral building blocks.

Future Trends

• Continued adoption of continuous‑flow synthesis to enhance throughput and reduce waste.
• Expansion of biocatalytic resolution technologies that lower energy consumption.
• Growing emphasis on green chemistry, with a shift toward renewable feedstocks and solvent‑free processes.
• Increased collaboration between fine‑chemical manufacturers and contract research organizations to accelerate drug discovery pipelines.